Reveal Pharmaceuticals’ Post

View organization page for Reveal Pharmaceuticals, graphic

485 followers

Exciting news from Reveal! We're thrilled to announce our NIH showcase at #BIO2024! Our latest developments include the initiation of Phase 2 clinical imaging studies of RVP-001, the groundbreaking gadolinium-free general-purpose MRI contrast agent. Additionally, Reveal’s pipeline fibrogenesis agent promises to revolutionize insight into active fibrotic disease and its treatment response. With the potential to benefit tens of millions of patients worldwide, Reveal’s innovative imaging drugs promise to usher in a new era of medical insight and enable therapeutic breakthroughs, while also enhancing environmental health and improving the resilience of the healthcare supply chain - a quadruple impact! Stay tuned for more updates as we continue to make strides towards a brighter, healthier future! Don't miss Srinivasan Mukundan's presentation on Monday, June 3rd, at 4:15 pm in Presentation Room 1 - please reach out to us directly if you are interested but unable to attend. We extend our grateful thanks to NIH SEED, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) The National Institutes of Health for their #SBIR support, as well as to MassVentures, Massachusetts Life Sciences Center, MassChallenge, and Endless Frontier Labs. Biotechnology Innovation Organization MassBio

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics